SpyGlass Pharma director reports initial share holdings
SpyGlass Pharma, Inc. director and officer Malik Y. Kahook reports his initial ownership of company securities.
Rhea-AI Filing Summary
SpyGlass Pharma, Inc. director and officer Malik Y. Kahook reports his initial ownership of company securities. He directly holds 873,978 shares of common stock. He also directly holds stock options to purchase 72,389 shares at $2.18, 191,874 shares at $2.87, and 170,475 shares at $7.11 per share.
Each option grant vests over four years under the company’s Amended and Restated 2019 Equity Incentive Plan. For each grant, 25% of the shares vest on the one-year anniversary of its Vesting Commencement Date, with the remaining shares vesting in equal monthly installments thereafter.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Kahook Malik Y.
Role
See remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 434,738 contracts (Direct);
Common Stock — 873,978 shares (Direct)
Footnotes (3)
- F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 6, 2023.
- F2. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 20, 2025.
- F3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 30, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does SpyGlass Pharma (SGP) Form 3 report for Malik Y. Kahook?
The Form 3 reports Malik Y. Kahook’s initial beneficial ownership in SpyGlass Pharma. He is a director and officer, and the filing lists his directly held common stock and stock options, including quantities, exercise prices, and vesting schedules under the company’s 2019 equity incentive plan.
What stock options in SpyGlass Pharma (SGP) does Malik Y. Kahook hold?
He holds three direct stock option grants: 72,389 shares at $2.18 expiring October 5, 2033; 191,874 shares at $2.87 expiring April 10, 2035; and 170,475 shares at $7.11 expiring July 23, 2035, all exercisable into SpyGlass Pharma common stock.
How do Malik Y. Kahook’s SpyGlass Pharma (SGP) options vest?
Each option vests over four years under the Amended and Restated 2019 Equity Incentive Plan. Twenty-five percent vests on the one-year anniversary of its Vesting Commencement Date, then one thirty-sixth of the remaining shares vests monthly, subject to continued service as a Service Provider.
What roles does Malik Y. Kahook hold at SpyGlass Pharma (SGP)?
The Form 3 lists him as both a director and an officer of SpyGlass Pharma. The remarks specify his officer roles as President, Chief Medical Officer, and Executive Chair, indicating significant leadership and governance responsibilities within the company’s management and board structure.
What is the event date for Malik Y. Kahook’s SpyGlass Pharma (SGP) Form 3?
The Form 3 uses February 5, 2026, as the Date of Event Requiring Statement. This date anchors when his reported holdings of common stock and derivative securities, including the detailed stock option positions, are being disclosed for regulatory purposes under Section 16(a).
AI-generated analysis. How Rhea-AI works. Not financial advice.
